Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Denton

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Rheumatology (Oxford, England)|November 18, 2004
Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to sclerodermaA L Lagan, P Pantelidis, E A Renzoni, et al.
European Neurology|January 31, 2008
Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexateG J D Hengstman, J L De Bleecker, E Feist, et al.
Annals of the Rheumatic Diseases|December 7, 2007
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseasesC P Denton, J E Pope, H-H Peter, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2015
Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary HypertensionK M Antoniou, G A Margaritopoulos, N S Goh, et al.
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Arthritis and Rheumatism|May 28, 2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisJ R Seibold, C P Denton, D E Furst, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 17, 2020
Whole blood gene expression profiling distinguishes systemic sclerosis-overlap syndromes from other subsetsP Moinzadeh, P Frommolt, M Franitza, et al.
Annals of the Rheumatic Diseases|July 27, 2006
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testM H Buch, C P Denton, D E Furst, et al.
Journal of Scleroderma and Related Disorders|December 21, 2018
Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definitionY A Suliman, C Bruni, S R Johnson, et al.
Arthritis and Rheumatism|October 31, 2007
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinaprilA E Gliddon, C J Doré, C M Black, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Rheumatology (Oxford, England)|November 18, 2004
Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to sclerodermaA L Lagan, P Pantelidis, E A Renzoni, et al.
European Neurology|January 31, 2008
Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexateG J D Hengstman, J L De Bleecker, E Feist, et al.
Annals of the Rheumatic Diseases|December 7, 2007
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseasesC P Denton, J E Pope, H-H Peter, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2015
Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary HypertensionK M Antoniou, G A Margaritopoulos, N S Goh, et al.
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Arthritis and Rheumatism|May 28, 2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisJ R Seibold, C P Denton, D E Furst, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 17, 2020
Whole blood gene expression profiling distinguishes systemic sclerosis-overlap syndromes from other subsetsP Moinzadeh, P Frommolt, M Franitza, et al.
Annals of the Rheumatic Diseases|July 27, 2006
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testM H Buch, C P Denton, D E Furst, et al.
Journal of Scleroderma and Related Disorders|December 21, 2018
Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definitionY A Suliman, C Bruni, S R Johnson, et al.
Arthritis and Rheumatism|October 31, 2007
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinaprilA E Gliddon, C J Doré, C M Black, et al.
Pageof 10